Skip to search formSkip to main contentSkip to account menu

SCH-530348

Known as: SCH 530348, SCH530348 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vorapaxar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The PAR 1 antagonist , SCH 79797 , alters platelet morphology and function indepen-dently of PARs
doi:10.1160/TH12-06-0389 Thromb Haemost 2013; 109: 164–167 Dear Sirs, Protease-activated receptors (PARs) are a family of four G… 
2015
2015
Bacterial Pulmonary Infection Proteinase-Activated Receptor 1 during Regulation of Neutrophilic Inflammation by Chambers
Neutrophils are key effector cells of the innate immune response to pathogenic bacteria, but excessive neutrophilic inflammation… 
Review
2012
Review
2012
Protease-Activated Receptor-1 Antagonists: Focus on SCH 530348
Currently available antiplatelet agents have shown improved short- and long-term clinical outcomes but are associated with… 
Review
2010
Review
2010
Thrombin receptor antagonism –the potential of antiplatelet medication SCH 530348
Importance of the field: Coronary artery disease is a leading cause of morbidity and mortality worldwide. Platelet activation and… 
Review
2010
Review
2010
Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events
Importance of the field: Aspirin, an irreversible inhibitor of thromboxane A2 production, in combination with clopidogrel, an… 
2010
2010
[Update on new antithrombotic treatments].
Update on new antithrombotic treatments Antithrombotic treatments are frequently prescribed in different clinical situations… 
2009
2009
Convergent Synthesis of Both Enantiomers of 4-Hydroxypent-2- ynoic Acid Diphenylamide for a Thrombin Receptor Antagonist Sch 530348 and Himbacine Analogues
Sch 530348 and many himbacine analogues were prepared by using 4-hydroxypent-2-ynoic acid diphenylamide as the only chiral… 
Review
2009
Review
2009
New antiplatelet agents.
PURPOSE OF REVIEW Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and… 
2009
2009
Improving antiplatelet therapy for atherothrombotic disease
Summary Morbidity and mortality in patients with atherothrombotic disease remain high despite the use of antiplatelet therapy… 
Review
2008
Review
2008
Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists.
Atherothrombosis is an acute complication that develops on the surface of a ruptured atheromatous plaque or as a consequence of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)